RedHill Biopharma
Proprietary Drugs for Gastrointestinal and Infectious Diseases
Startup Public Health Tech & Life Sciences Est. 2009
🌐 WebsiteLinkedInTwitterCareers
Total Raised
$281.75M
Public
Last Round
$4M
21 rounds
Investors
14
14 public
Team
4
11-50 employees
Confidence
90/100
News
188
articles
Patents
1
About
RedHill Biopharma is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on its promises, to build a company at the forefront of gastrointestinal and infectious diseases management. Its two FDA-approved drugs are promoted in the U.S. by a dedicated and experienced sales team: Talicia and Aemcolo. RedHill has also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business Model
B2B
Tags
inflammatory-diseasescrohn's-diseasebiopharmaceuticaloral-drugsmedical-productsgastroenterologypharmaceuticalsoncologyhealthcare-providersorphan-drugpatientsinfectious-disease
Funding & Events
Oct 2025
PIPE $4M
Cumberland Pharmaceuticals (Lead)
Oct 2019
PIPE $36M
Cosmo Pharmaceuticals (Lead)
Nov 2021
PIPE $10M
Undisclosed Investor(s)
Nov 2021
Exit Undisclosed
Nov 2010
Seed $10M
Lautman Foundation, Fischer Pharmaceutical Laboratories Ltd, Shmuel Kabili, Fidelity Ventures
May 2022
PIPE $15M
Undisclosed Investor(s)
Mar 2021
Exit Undisclosed
Jul 2015
Exit Undisclosed
Jan 2024
PIPE $8M
Undisclosed Investor(s)
Jan 2014
PIPE $11.7M
Excellence Nessuah Investment House, Sphera Global Healthcare Fund, Yelin Lapidot Investment House, Migdal Insurance and Financial Holdings
Jan 2012
Exit Undisclosed
Feb 2020
Debt Financing $115M
HealthCare Royalty Partners
Feb 2020
Exit Undisclosed
Feb 2015
Exit Undisclosed
Dec 2023
Non-equity $4.8M
U.S. Government
Dec 2022
Exit Undisclosed
Dec 2018
Exit Undisclosed
Dec 2016
Exit Undisclosed
Dec 2012
PIPE $6.5M
OrbiMed, Broadfin Capital
Dec 2012
Exit Undisclosed
Apr 2024
PIPE $1.25M
Undisclosed Investor(s)
Apr 2023
PIPE $6M
Undisclosed Investor(s)
News (188)
Oct 22, 2025 · finance.yahoo.com
growth-negative
RedHill Biopharma Receives Nasdaq Staff Determination Notification
Oct 22, 2025 · www.prnewswire.com
growth-negative
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the...
Partners
Oct 20, 2025 · finance.yahoo.com
growth-positive
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
PartnersInvestment
Oct 20, 2025 · www.prnewswire.com
growth-positive
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S....
PartnersInvestmentCustomers
Oct 20, 2025 · finance.yahoo.com
growth-positive
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
PartnersInvestmentCustomers
Oct 6, 2025 · finance.yahoo.com
growth-positive
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
Partners
Oct 6, 2025 · www.prnewswire.com
growth-positive
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments,...
Product StageCustomersPartners
Sep 29, 2025 · www.prnewswire.com
growth-positive
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed...
Sep 29, 2025 · finance.yahoo.com
growth-positive
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
Sep 5, 2025 · finance.yahoo.com
growth-positive
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
Product StageCustomersPartnersInvestment
Aug 20, 2025 · finance.yahoo.com
growth-positive
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
Aug 20, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York...
Aug 18, 2025 · finance.yahoo.com
growth-positive
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
CustomersFDA approved/pending approval
Aug 18, 2025 · www.prnewswire.com
growth-positive
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S....
CustomersFDA approvedPartners
Jul 21, 2025 · www.prnewswire.com
growth-positive
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium...
Product StagePartners
Jul 21, 2025 · finance.yahoo.com
growth-positive
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
Product StagePartners
Jul 1, 2025 · finance.yahoo.com
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Jul 1, 2025 · finance.yahoo.com
growth-positive
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Product Stage
Jul 1, 2025 · www.prnewswire.com
growth-positive
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer...
Product StagePartners
May 13, 2025 · finance.yahoo.com
growth-positive
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
Product StagePartners
+ 168 more articles
Details
Product Stage
Released
Employees
11-50
Exact Count
48
District
Center District
Founded
2009
Registrar
514304005
Crunchbase
redhill-biopharma
Locations
21 Haarbaa St., 6473921, Tel Aviv, Israel
8045 Arco Corporate Drive, Raleigh, NC, USA
Links
Website
www.redhillbio.com/home/default.aspx
LinkedIn
Profile
Twitter
Profile
Careers
Open positions
Admin
Last Update
Oct 23, 2025
Verified by
Yanina Wainscheinker
Missing
video or image, markets, not claimed
Team (4)
Dror Ben-Asher
Co-Founder & CEO
Founder
Guy Goldberg
CBO
Gilead Raday
COO
Adi Frish
SVP BD & Licensing
Internal
Created by
Arielle Smolin (ari.smolin@gmail.com)
Created
2014-07-14T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Public on NASDAQ on Jan, 2012;
Finder · RedHill Biopharma · 2026